AstraZeneca has paused a 200 million pound sterling ($271 million) investment in its Cambridge, England research site, a ...

The pause is the latest blow to the U.K.’s biotech industry, which is still reeling from Merck’s recently announced R&D ...

Like approved Alzheimer’s meds Kisunla (donanemab) and Leqembi (lecanemab), as well as the discontinued Aduhelm (aducanemab), ...

Not all cardiac arrests can be treated with an electric shock. In fact, most of them—about 80%—are ineligible for ...

Philips and Masimo are renewing their years-long collaboration in patient monitoring, with what they describe as an expanded ...

With its head of U.S. business Julie Kim sliding up to the CEO spot next June, Takeda has locked in a replacement in Rhona ...